CF
TRVI icon

Cantor Fitzgerald’s Trevi Therapeutics TRVI Stock Holding History

Cantor Fitzgerald’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,861
Closed -$465K – 373
2025
Q3 		$465K Sell
50,861
-49,140
-49% -$368K ﹤0.01% 300
2025
Q2 		$547K Buy
+100,001
New +$622K 0.01% 220
2025
Q1 		– Sell
-20,000
Closed -$82K – 392
2024
Q4 		$82K Buy
+20,000
New +$64K ﹤0.01% 214

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Cantor Fitzgerald's TRVI Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 50,861 shares — an estimated $465K sold.

Cantor Fitzgerald first reported a position in TRVI in Q4 2024 and held it in 3 quarters. The position peaked at $547K in Q2 2025. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • Cantor Fitzgerald reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 50,861 Trevi Therapeutics shares in Q4 2025, an estimated $465K.
  • Cantor Fitzgerald first reported a position in Trevi Therapeutics in Q4 2024 and held it in 3 quarters.
  • Cantor Fitzgerald's Trevi Therapeutics position peaked at $547K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.